title: [Second line therapy for castration-resistant prostate cancer (CRPC)].
abstract: Every year in Germany approximately 12,000 men die of castration-resistant prostate cancer even though early detection using PSA-based diagnostics allows more patients to be diagnosed with a curable cancer. An established first line therapy at this stadium is docetaxel chemotherapy, given in a 3-week regimen, providing an overall survival advantage of 2 months. In 6-9 months, the patients treated primarily with docetaxel will progress to a docetaxel-insensitive phase which requires a secondary systemic therapy. Increasing understanding of molecular signal transduction has permitted a growing variety of promising modern drugs, including cabazitaxel, sipuleucel-T and abiraterone. More prospective clinical data will provide a large variety of different therapy combinations, sequence therapies or other therapy regimens particularly for selected subgroups of patients with castration-resistant prostate cancer.
authors: Klinik für Urologie, onkologische Urologie und Kinderurologie, Krankenhaus Düren, Roonstraße 30, 52351 Düren, Deutschland. bmolitor@gmx.de
authors: B
authors: B
authors: Molitor
authors: C
authors: C
authors: Börgermann
mesh_terms: D000736:Androstenes; D000737:Androstenols / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D000077143:Docetaxel; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011944:Receptors, Androgen / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D014020:Tissue Extracts / Q000008:administration & dosage
chemical_list: D000736:Androstenes; D000737:Androstenols; D019496:Cancer Vaccines; D011944:Receptors, Androgen; D043823:Taxoids; D014020:Tissue Extracts; D000077143:Docetaxel; C552428:cabazitaxel; C511774:sipuleucel-T; D008942:Mitoxantrone; C089740:abiraterone